相似文献
1
Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice.
Ther Adv Med Oncol. 2017 Jun;9(6):405-414. doi: 10.1177/1758834017704329. Epub 2017 Apr 26.
2
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12.
3
EGFR mutation testing in non-small cell lung cancer (NSCLC).
J Infect Public Health. 2012 Dec;5 Suppl 1:S31-4. doi: 10.1016/j.jiph.2012.09.008. Epub 2012 Nov 4.
4
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
J Thorac Oncol. 2010 Oct;5(10):1706-13. doi: 10.1097/JTO.0b013e3181f1c8de.
5
EGFR mutation testing of lung cancer patients - Experiences from Vestfold Hospital Trust.
Acta Oncol. 2016;55(2):149-55. doi: 10.3109/0284186X.2015.1062537. Epub 2015 Aug 26.
6
Management and future directions in non-small cell lung cancer with known activating mutations.
Am Soc Clin Oncol Educ Book. 2014:e353-65. doi: 10.14694/EdBook_AM.2014.34.e353.
7
The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer.
Transl Lung Cancer Res. 2015 Apr;4(2):119-25. doi: 10.3978/j.issn.2218-6751.2015.01.05.
8
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Lung Cancer. 2019 Nov;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23.
9
Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma.
BMC Cancer. 2019 Feb 26;19(1):175. doi: 10.1186/s12885-019-5374-1.
10
Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.
Intern Med J. 2014 Jun;44(6):575-80. doi: 10.1111/imj.12449.
引用本文的文献
1
AL365181.3 as a novel prognostic biomarker for lung adenocarcinoma.
Sci Rep. 2025 Feb 18;15(1):5853. doi: 10.1038/s41598-025-90008-0.
2
RASGEF1C as a novel prognostic biomarker for LUAD.
Discov Oncol. 2024 Dec 23;15(1):825. doi: 10.1007/s12672-024-01718-2.
3
The deubiquitinating protein OTUD6B promotes lung adenocarcinoma progression by stabilizing RIPK1.
Biol Direct. 2024 Jun 16;19(1):46. doi: 10.1186/s13062-024-00489-8.
4
Identification of ITGB4 as a novel tumor promoting gene in lung adenocarcinoma (LUAD).
Oncol Rep. 2024 Feb;51(2). doi: 10.3892/or.2023.8689. Epub 2023 Dec 22.
5
Identification of key genes and biological pathways in lung adenocarcinoma by integrated bioinformatics analysis.
World J Clin Cases. 2023 Aug 16;11(23):5504-5518. doi: 10.12998/wjcc.v11.i23.5504.
6
Role of microRNAs in regulation of doxorubicin and paclitaxel responses in lung tumor cells.
Cell Div. 2023 Jul 21;18(1):11. doi: 10.1186/s13008-023-00093-8.
7
The relation between epidermal growth factor receptor mutations profiles and smoking patterns in patients with lung adenocarcinoma: A cross-sectional study.
Health Sci Rep. 2023 Jul 5;6(7):e1369. doi: 10.1002/hsr2.1369. eCollection 2023 Jul.
8
Bevacizumab loaded CalliSpheres® bronchial arterial chemoembolization combined with immunotherapy and targeted therapy for advanced lung adenocarcinoma.
Front Pharmacol. 2023 May 22;14:1170344. doi: 10.3389/fphar.2023.1170344. eCollection 2023.
9
Circ_0039908/miR-let-7c/RRM2 axis was identified played an important role in lung adenocarcinoma by integrated analysis.
J Cancer. 2022 Jul 18;13(10):2988-2999. doi: 10.7150/jca.72789. eCollection 2022.
10
CD73 (NT5E) Promotes the Proliferation and Metastasis of Lung Adenocarcinoma through the EGFR/AKT/mTOR Pathway.
Biomed Res Int. 2022 Jun 29;2022:9944847. doi: 10.1155/2022/9944847. eCollection 2022.
本文引用的文献
1
New and emerging targeted treatments in advanced non-small-cell lung cancer.
Lancet. 2016 Sep 3;388(10048):1012-24. doi: 10.1016/S0140-6736(16)31473-8. Epub 2016 Sep 1.
2
Lung cancer: current therapies and new targeted treatments.
Lancet. 2017 Jan 21;389(10066):299-311. doi: 10.1016/S0140-6736(16)30958-8. Epub 2016 Aug 27.
3
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Lancet Oncol. 2016 Apr;17(4):452-463. doi: 10.1016/S1470-2045(15)00614-2. Epub 2016 Mar 11.
4
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
J Clin Oncol. 2016 Mar 1;34(7):721-30. doi: 10.1200/JCO.2015.63.4600. Epub 2016 Jan 4.
5
KRAS mutant lung cancer: progress thus far on an elusive therapeutic target.
Clin Transl Med. 2015 Dec;4(1):35. doi: 10.1186/s40169-015-0075-0. Epub 2015 Dec 14.
6
c-Met as a Target for Personalized Therapy.
Transl Oncogenomics. 2015 Nov 23;7(Suppl 1):13-31. doi: 10.4137/TOG.S30534. eCollection 2015.
7
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
J Clin Oncol. 2016 Mar 1;34(7):661-8. doi: 10.1200/jco.2015.63.9443. Epub 2015 Nov 23.
8
Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
Clin Cancer Res. 2015 May 15;21(10):2227-35. doi: 10.1158/1078-0432.CCR-14-2791.
9
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Cancer Discov. 2015 Aug;5(8):850-9. doi: 10.1158/2159-8290.CD-15-0285. Epub 2015 May 13.
10
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
J Clin Oncol. 2015 Mar 20;33(9):992-9. doi: 10.1200/JCO.2014.58.3302. Epub 2015 Feb 9.
Zotero 插件